BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Everest Medicines partners with Shanghai Pharma subsidiary to commercialize XERAVA in China

According to the MoU, Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA (eravacycline) in China. SPH Kyuan'...

April 19, 2023 | News

HUTCHMED's Fruquintinib NDA Accepted in China for 2nd-Line Gastric Cancer

Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towa...

April 18, 2023 | News

Shanghai Biopharma Presents Phase I Data for Novel CAR-T in Advanced Liver Cancer

Early results indicate that C-CAR031 is well tolerated with promising anti-tumor activity seen and objective responses in several patients to date, includi...

April 18, 2023 | News

Ascentage Pharma's Three Studies Highlight New Potential Indications

"The data we presented at this year's AACR Annual Meeting highlight the three drug candidates' potential for clinical development and promising syn...

April 18, 2023 | News

NovoSense NST1002 improves CGM accuracy with glucose monitoring black tech.

Principle and technical difficulties of CGM CGM allows real-time monitoring of glucose concentration in subcutaneous tissue fluid by implanting glucose se...

April 18, 2023 | News

Zenshine's ZX-7101A Meets Primary Endpoint in Phase 2 Study for Adult Flu Treatment

Interim analysis of the phase 2 cohort of ZX-7101A phase 2/3 adaptive design pivotal study (registration number: CTR20221729), a multicenter, randomized, d...

April 17, 2023 | News

AffaMed Therapeutics Approved for Phase 3 Trial of DEXTENZA® in China for Eye Surgery Inflammation and Pain

In addition, AffaMed is pleased to announce that DEXTENZA has recently been approved in Macau, China for the treatment of ocular itchin...

April 17, 2023 | News

Minghui Pharma's MH004 Cream Succeeds in Phase 2 Trial for Atopic Dermatitis, Global Phase 3 MRCT Cleared by FDA

Study met both primary and all key secondary endpoints Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score was -78.7% in...

April 14, 2023 | News

Zenshine's ZX-7101A meets primary endpoint in Phase 2 flu treatment study

Interim analysis of the phase 2 cohort of ZX-7101A phase 2/3 adaptive design pivotal study (registration number: CTR20221729), a multicenter, randomized, d...

April 14, 2023 | News

CPHI Japan: the rise of Chinese innovation the big macro story for APAC in 2023

“Historically, we have seen a dual strategy of focusing on China and the US for emerging innovators in China. However, a series of recent setbacks wi...

April 13, 2023 | News

Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

Currently, commercially available cell therapies, such as CD19 CAR-T, are designed for the treatment of B cell lymphoma or acute lymphoblastic leukemia. Tr...

April 12, 2023 | News

Boan Biotech's Biologics License Application for Boyounuo® (Bevacizumab Injection) Accepted in Brazil

Envisioned to be "a leading global biopharmaceutical company", Boan Biotech develops biologics for both Chinese and international markets, including E...

April 12, 2023 | News

JW Therapeutics' Relma-cel approved for systemic lupus erythematosus trial.

SLE is a complex autoimmune disease with diverse clinical manifestations involving many organs and systems. It is estimated that China has 1 mill...

April 11, 2023 | News

Asieris subsidiary obtains "Drug Distribution License" for commercialization strategy.

Hainan Asieris' acquisition of the Drug Distribution Licence is a critical step towards improvement in the quality of drug circulation services, standardiz...

April 11, 2023 | News

Stay Connected